New York Bone & Joint Specialists: New Invention Stops or Delays the Progression of Osteoarthritis of the Knee

April 1, 2021

New York Bone & Joint Specialists is at the forefront of orthopedic technology, with an exciting invention focused on preventing the development and/or progression of osteoarthritis of the knee.

At the same time, this invention can be used to promote and accelerate the healing of any orthopedically repaired tissue.

Leon E. Popovitz, MD, co-founder of New York Bone & Joint Specialists and top orthopedic surgeon in NYC, has invented a bone and joint implant device that has the potential to counteract the effects of osteoarthritis. As a result, the device would diminish the need for joint replacement surgery, and save billions of dollars in medical costs.

The invention is an anchor that increases blood circulation to soft tissue. It features a unique network of channels that are designed to maximize blood flow and rejuvenate vital structures, such as the meniscus, in a degenerating knee. Thus, a patient who suffers from the beginnings of osteoarthritis of the knee may completely avoid the long and painful process of managing their deteriorating joint and eventually receiving a knee replacement. Instead, their knee may become rejuvenated without the need for joint replacement surgery.

Dr. Popovitz and his team have completed bench testing and cadaver intraoperative testing for this patented implant. Further studies are still in process.

“Millions of people suffer from knee osteoarthritis and millions undergo extensive joint replacement therapy,” says Dr. Popovitz. “My implant serves to replenish circulation to the meniscus, which functions by protecting the knee joint from degeneration. The invention, therefore, works by preserving the knee joint itself.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”